TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25226328
Drug: Massage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage treatment for 15 minutes by physiotherapist, consisting of light stroking, milking, friction, and skin rolling.
Study: 19926058
Drug: High-dose sirolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sirolimus
Study: 2478778
Drug: Transdermally delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermally delivered nitroglycerin (NTG 10 mg/24 h)
Study: 17171330
Drug: Collagen implant
Normalized name: Collagen implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen implant (CMI) with high tibial valgus osteotomy
Study: 14501397
Drug: Moist Exposed
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moist Exposed Burn Ointment (MEBO)
Study: 3890394
Drug: muzolimine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: muzolimine (20 mg o.d.)
Study: 3890394
Drug: acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol (400 mg o.d.)
Study: 29197947
Drug: Adapted dialectical
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted dialectical behavior therapy (DBT) skills training for 10 sessions
Study: 30439812
Drug: D +
Normalized name: Liver Desiccated + B
Approvals — FDA: no, EMA: no, PMDA: no
Description: D + ASA (Duloxetine + Acetylsalicylic Acid 100 mg)
Study: 27029487
Drug: Deferiprone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (20 mg/kg/day)
Study: 24908096
Drug: Standard speech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard speech and language therapy (dose determined by individual needs, not exceeding eight weeks of treatment)
Study: 24908096
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard care with no speech and language therapy input for at least six months post-randomization)
Study: 10857839
Drug: Timolol with
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol with systemic beta-blockers
Study: 10857839
Drug: Brimonidine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine with systemic beta-blockers
Study: 10857839
Drug: Brimonidine without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine without systemic beta-blockers
Study: 24854306
Drug: ACTH stimulation
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH stimulation test with 250 μg of synthetic ACTH administered intravenously on Days 1, 2, 3, 5, and 7 after traumatic injury
Study: 24854306
Drug: CIRCI patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIRCI patients with Δcortisol < 9 μg/dL
Study: 24854306
Drug: Δcortisol <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δcortisol < 9 μg/dL
Study: 2163701
Drug: Antibiotic-impregnated fine-mesh
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic-impregnated fine-mesh greased gauze covering remaining areas of the wounds
Study: 326347
Drug: Vole bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vole bacillus vaccine
Study: 31277561
Drug: Canakinumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (150 mg subcutaneously)
Study: 25614164
Drug: Riociguat, individually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat, individually adjusted up to a maximum dose of 2.5 mg three times daily
Study: 23519546
Drug: nebivolol 5-40
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebivolol 5-40 mg/day
Study: 19172849
Drug: Statin or
Normalized name: nystatin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin or immunosuppressive therapy
Study: 16878035
Drug: rHuEPO 40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO 40,000 units administered weekly for up to 12 doses
Study: 8087328
Drug: ICI 204,219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204,219 40 mg
Study: 7767514
Drug: ICI 204,219
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 204,219 100 mg
Study: 6500225
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg four times a day
Study: 30665602
Drug: Simultaneous tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous tobacco intervention (TI) combining web-based counseling with nicotine replacement therapy (NRT) during weeks 1-12.
Study: 30665602
Drug: Sequential tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential tobacco intervention (TI) delayed until weeks 13-24.
Study: 25684233
Drug: Vanoxerine 400
Normalized name: Vanoxerine
DrugBank: Vanoxerine (DB03701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanoxerine 400 mg
Study: 22160549
Drug: Lidocaine pretreatment
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine pretreatment (1% lidocaine 2 ml)
Study: 11853711
Drug: 0.12% isopropyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% isopropyl unoprostone (Rescula) applied twice a day for 21 days
Study: 11853711
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice a day for 21 days
Study: 9798136
Drug: 0.625‐mg conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625‐mg conjugated equine estrogen plus 5‐mg medroxyprogesterone acetate (MPA)
Study: 9798136
Drug: 0.625‐mg conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625‐mg conjugated equine estrogen plus 2.5‐mg MPA
Study: 7825160
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of warfarin per day for 3 days (Group I)
Study: 7825160
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of warfarin twice a day for 2 or 3 days (Group II)
Study: 3364147
Drug: 10 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg.kg‐1 of 1.5% lidocaine
Study: 24302687
Drug: Early iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early iron (EI) supplementation (2 mg/kg/day elemental iron)
Study: 22273632
Drug: IL‐1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL‐1 receptor antagonist (IL‐1Ra) 150 mg
Study: 14739212
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin 100 mg daily
Study: 14739212
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin enoxaparin 40 mg
Study: 10690604
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion (50 micrograms/h for 12 hours following initial 50 micrograms i.v. bolus)
Study: 9369912
Drug: Cisplatin‐based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin‐based chemotherapy regimen
Study: 8335204
Drug: Heme arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heme arginate (3 mg/kg)
Study: 8335204
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of heme arginate (3 mg/kg) and tin protoporphyrin (1 mumol/kg)
Study: 2544688
Drug: Intermittent metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent metoclopramide (regimen A): lorazepam 1 mg orally, dexamethasone 10 mg IV every four hours for three doses, diphenhydramine 0.5 mg/kg IV every four hours for three doses, metoclopramide 1 mg/kg IV bolus every two hours for six doses
Study: 2544688
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion metoclopramide (regimen B): identical to regimen A except metoclopramide was administered as 1 mg/kg IV bolus followed by 0.5 mg/kg/h for ten hours
Study: 23849614
Drug: Biscem cement
Normalized name: Cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biscem cement (Sub-group A, L, C)
Study: 23849614
Drug: Maxcem Elite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxcem Elite (Sub-group A, L, C)
Study: 19833860
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg/d for 7 days
Study: 19833860
Drug: Telbivudine 1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 1800 mg/d for 7 days
Study: 19833860
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg (positive calibrator)
Study: 16721396
Drug: Natural mixed
Normalized name: Xymogen Optimag Neuro Natural Mixed Berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural mixed carotenoids supplementation (120,000 IU of beta-carotene daily)
Study: 20099987
Drug: Ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40 mg/day
Study: 10192829
Drug: Ziprasidone 80
Normalized name: ziprasidone 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 80 mg/day
Study: 11199944
Drug: Ziprasidone 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 120 mg/day
Study: 20099987
Drug: Ziprasidone 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 160 mg/day
Study: 12177583
Drug: Ziprasidone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (all doses)
Study: 8355037
Drug: 1 year
Normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 year of adjuvant CMFVP chemotherapy
Study: 8355037
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of adjuvant CMFVP chemotherapy
Study: 16226759
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg sublingual nitroglycerin
Study: 18447219
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Smecta (Control)
Study: 18447219
Drug: Drug-separated moxibustion
Normalized name: serrated swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-separated moxibustion at Shenque (CV 8)
Study: 8897357
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin (PCN) administered at a dose of 1,200,000 u, intramuscularly at 3-week intervals for at least one year.
Study: 1677774
Drug: Lorazepam (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (4.5 mg)
Study: 6647190
Drug: Metronidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (500 mg)
Study: 10150324
Drug: Cefoxitin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (1 g)
Study: 27676664
Drug: Pulsed dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dose radiofrequency followed by continuous thermal radiofrequency ablation
Study: 18554712
Drug: LT-patch (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LT-patch (37.5 mug of heat-labile toxin from E. coli)
Study: 2146370
Drug: resection and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: resection and continuous hepatic artery infusion (CHAI) of fluorodeoxyuridine (FUdR) in arm A2
Study: 1032070
Drug: Buprenorphine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.15 mg and 0.3 mg)
Study: 1032070
Drug: Buprenorphine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.6 mg and 1.2 mg)
Study: 7628027
Drug: Morphine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (150 micrograms.kg‐1)
Study: 28353611
Drug: Intra-articular lumbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular lumbar facet joint corticosteroid injection (ICI)
Study: 25393089
Drug: Systemic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroid therapy
Study: 29797981
Drug: Steroid combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid combined with dehydrant therapy
Study: 22424787
Drug: Oxytocin (24IU)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (24IU) administered in the second session
Study: 11782325
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of racemic methadone (initial doses of 3 to 6 mg followed by 6 to 12 mg over 24 hr)
Study: 9633672
Drug: 100-g TFD
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-g TFD (tryptophan-free amino acid drink)
Study: 7866680
Drug: Insulin hypoglycaemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin hypoglycaemia (IH) test
Study: 1967919
Drug: Terfenadine, 60
Normalized name: Terfenadine, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 60 mg BID
Study: 23680127
Drug: ABThera Open
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABThera Open Abdomen Negative Pressure Therapy System
Study: 9493805
Drug: MEDI‐493 (palivizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI‐493 (palivizumab) 3 mg/kg
Study: 9493805
Drug: MEDI‐493 (palivizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI‐493 (palivizumab) 10 mg/kg
Study: 9493805
Drug: MEDI‐493 (palivizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI‐493 (palivizumab) 15 mg/kg
Study: 2528256
Drug: 20% azelaic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% azelaic acid cream
Study: 60566
Drug: Timolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (10 mg thrice daily)
Study: 28835400
Drug: Vertebral angioplasty/stenting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertebral angioplasty/stenting plus best medical treatment (BMT)
Study: 23800627
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein formula (HP: 2.05 and 3.2 g/100 mL)
Study: 23800627
Drug: Lower protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower protein formula (LP: 1.25 and 1.6 g/100 mL)
Study: 11246738
Drug: Various interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various interventions in phase 3 trials for urinary bladder cancer therapy
Study: 2697239
Drug: Lidocaine 100
Normalized name: lidocaine 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 100 mg
Study: 7954529
Drug: Intrapleural OK-432
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural OK-432 injection
Study: 7954529
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intrapleural OK-432 injection)
Study: 2888424
Drug: Terfenadine 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 180 mg
Study: 29452584
Drug: P1000/Ca1000 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: P1000/Ca1000 (1000 mg/d phosphorus and 1000 mg/d calcium)
Study: 27151156
Drug: UC-no additional
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: UC-no additional therapy.
Study: 10867764
Drug: Transmyocardial revascularization
Normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmyocardial revascularization (TMR) as an adjunct to coronary artery bypass grafting (CABG)
Study: 3966424
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc supplements
Study: 13130174
Drug: 30-45 min
Normalized name: salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30-45 min of physiotherapy twice daily
Study: 1519783
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine (8 micrograms.kg‐1 in 4 ml over 2 min)
Study: 1519783
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (8 micrograms.kg‐1 in 10 ml over 14 min)
Study: 20305057
Drug: Biolimus A9
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Biolimus A9 (BA9) at doses from 0.0075 mg/kg to 0.25 mg/kg
Study: 19930788
Drug: Azelastine 0.15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine 0.15% and 0.10% nasal sprays
Study: 2442536
Drug: Bornaprolol 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bornaprolol 80 mg
Study: 2442536
Drug: Bornaprolol 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bornaprolol 120 mg
Study: 2442536
Drug: Bornaprolol 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bornaprolol 240 mg
Study: 2442536
Drug: Bornaprolol 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bornaprolol 480 mg
Study: 2442536
Drug: Bornaprolol 960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bornaprolol 960 mg
Study: 2442536
Drug: Bornaprolol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bornaprolol (various doses)
Study: 29807824
Drug: 1·1 GBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1·1 GBq radioactive iodine after thyroid hormone withdrawal
Study: 29807824
Drug: 3·7 GBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3·7 GBq radioactive iodine after thyroid hormone withdrawal
Study: 25019111
Drug: Analgesic (only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic (only if required)
Study: 1286495
Drug: Flumazenil (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.7 mg, intravenously)
Study: 4023558
Drug: Praziquantel therapy
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel therapy
Study: 30475957
Drug: Continuous Calorie
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Calorie Restriction (CCR) - daily energy deficit ∼20%
Study: 28749419
Drug: 28 g
Normalized name: SM Syringe 28 g, 0.5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 g of whole, lightly salted roasted almonds
Study: 26785372
Drug: BCAA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA + OA supplementation (16 g BCAA and 12 g OA)
Study: 10823258
Drug: Weekly self-testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly self-testing and self-dosing
Study: 9059217
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg kg‐1
Study: 1287614
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg three times daily
Study: 6337988
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg three times daily
Study: 31413542
Drug: Amlodipine 2.5‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5‐5 mg/day
Study: 16985182
Drug: Regimen C
Normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C (high-intensity therapy with higher doses of doxorubicin, cyclophosphamide, and ifosfamide)
Study: 16985182
Drug: Increasing exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing exposure to ifosfamide (90 to 140 g/m2), cyclophosphamide (9.6 to 17.6 g/m2), and doxorubicin (375 to 450 mg/m2)
Study: 16358235
Drug: Cefotaxime-heparin lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime-heparin lock solution
Study: 12028163
Drug: Geriatric Evaluation
Normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric Evaluation and Management Unit (GEMU) treatment
Study: 12028163
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional treatment in Department of Internal Medicine)
Study: 9145823
Drug: Fleroxacin 400
Normalized name: fleroxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 400 mg od for 10 days
Study: 9145823
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg bd for 10 days
Study: 29204924
Drug: Bleomycin microneedle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin microneedle patch
Study: 26944837
Drug: Short-acting β-agonists
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting β-agonists
Study: 25509976
Drug: Intracervical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical anesthesia (10 ml %2 prilocaine)
Study: 19469296
Drug: Morphine 0.5
Normalized name: morphine 0.5 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.5 mg/ml + placebo (M-group)
Study: 12522747
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg intravenously or orally every 12 h)
Study: 8681490
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (2 mg nicotine per piece, at least six pieces per day)
Study: 1947721
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion without volume expansion
Study: 1947721
Drug: Control (Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Day B: no insulin and glucose infusion)
Study: 27128612
Drug: MF 800 µg
Normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MF 800 µg + F 20 µg coadministered (MF + F)
Study: 20702114
Drug: Candesartan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (4 mg/day)
Study: 17130203
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/day)
Study: 17211270
Drug: Dalteparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (5000 U) given subcutaneously once daily for 6 weeks postoperatively
Study: 12210616
Drug: Network meta-analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Network meta-analysis techniques for treatment comparisons
Study: 273143
Drug: Overall (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (both intrathecal chemotherapy groups)
Study: 25195547
Drug: n-3 fish
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fish oil 3000 mg/day
Study: 21892200
Drug: Antofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antofloxacin (400 mg on day 1 and 200 mg on days 2 to 5)